The Medication(s) listed below have been approved by the Food & Drug Administration (FDA) as orphan products for treatment of this condition. There may be other products available
that are not considered orphan products.
Brentuximab vedotin (Brand name: Adcetris)
- Manufactured by
Seattle Genetics, Inc
FDA-approved indication: March 2018, brentuximab vedotin (Adcetris) was approved for the treatment of adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with chemotherapy. In August 2015, it was approved for treatment of patients with classical Hodgkin lymphoma at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT). In August 2011, it was approved for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates.
National Library of Medicine Drug Information PortalMedline Plus Health Information